BRCA-mutant breast cancer

FDA grants priority review to AstraZeneca’s sNDA for breast cancer therapy
Pharmaceutical Business Review
Wed, 12/1/21 - 10:21 am
FDA
AstraZeneca
Lynparza
BRCA-mutant breast cancer
Moving up the lines, AstraZeneca stakes another PhIII win for Lynparza as adjuvant breast cancer therapy
Endpoints
Wed, 02/17/21 - 11:21 am
AstraZeneca
Merck
Lynparza
clinical trials
BRCA-mutant breast cancer
breast cancer
AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer
Pharmaforum
Wed, 04/10/19 - 09:46 am
AstraZeneca
Merck
Lynparza
BRCA-mutant breast cancer
Europe
breast cancer
FDA approves Pfizer's drug for advanced breast cancer
Reuters
Tue, 10/16/18 - 08:40 pm
FDA
Pfizer
PARP inhibitors
talazoparib
breast cancer
BRCA-mutant breast cancer
Can Kadcyla give Roche a softer landing when Herceptin biosims hit? New data could help
Fierce Pharma
Mon, 10/15/18 - 11:47 pm
Roche
Kadcyla
Herceptin
BRCA-mutant breast cancer
Pfizer's PARP Inhibitor Talazoparib Gets FDA Priority Review and EMA Submission
CP Wire
Thu, 06/7/18 - 12:07 pm
Pfizer
talazoparib
BRCA-mutant breast cancer
breast cancer
metastatic breast cancer
FDA
EMA
priority review
Pfizer's PARP Inhibitor Talazoparib Gets FDA Priority Review and EMA Submission
Thu, 06/7/18 - 12:04 pm
Pfizer
talazoparib
BRCA-mutant breast cancer
breast cancer
AstraZeneca's Lynparza Slows Breast Cancer Caused By BRCA Mutations By 42%
Forbes
Sun, 06/4/17 - 11:53 am
AstraZeneca
Lynparza
breast cancer
BRCA-mutant breast cancer
ASCO 2017
AbbVie breast cancer drug falls short in Phase 2
BioPharma Dive
Wed, 12/7/16 - 07:45 pm
AbbVie
breast cancer
veliparib
PARP inhibitors
BRCA-mutant breast cancer